H.C. Wainwright raised the firm’s price target on Instil Bio (TIL) to $125 from $105 and keeps a Buy rating on the shares after the company released Phase 1/2 dose escalation data for AXN-2510 in first-line non-small cell lung cancer. The firm increased its probability of approval to 35% from 25%.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TIL:
- Biotech Alert: Searches spiking for these stocks today
- Instil Bio Partners with ImmuneOnco for Cancer Therapy
- Instil Bio price target lowered to $105 from $110 at H.C. Wainwright
- Instil Bio’s Phase 2 trial of asset AXN-2510 to complete enrollment in China
- Instil Bio reports Q1 EPS ($1.32) vs ($2.39) last year